Shivani Nyati, the Head of Wealth at Swastika Investmart, has assigned an 'Avoid' rating to this IPO, citing the company's disappointing financial performance. The firm incurred significant losses in the fiscal year 2022-23, with some indications of improvement in FY24. However, she believes the valuation of the public offering is not favorable for investors.
Suraksha Diagnostic IPO Day 3: Will the issue sail through on final day? Check subscription and GMP - The Economic TimesSuraksha Diagnostic IPO Day 2: Check subscription status, GMP, and more - Business StandardSuraksha Diagnostic IPO closes today: GMP remains flat; Should you bid? - Business StandardSuraksha Diagnostics IPO day 2: GMP, subscription status, review, other details. Apply or not? - Mint
